GRDN · Guardian Pharmacy Services, Inc.
$41.00
+0.22 (+0.54%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$2.61B
Shares
63.34M
Volume · Sep 30
540.21K
Avg daily vol (3M)
477.5K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$40.78
Open$41.23
Day$40.54–41.89
52W close$23.41–48.00
Avg vol 30d606K
Short int2.4M · 3.8% float · 3.7d
Short vol80%
Last earningsAug 6, 2026
DataSep 2024–Sep 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.46B
Trailing 12 months
Net income (TTM)
$65.91M
Trailing 12 months
Revenue growth YoY
+2.2%
Year over year
Operating margin
5.8%
Trailing 12 months
P / E (TTM)
39.6
Trailing earnings · reciprocal yield 2.5%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+55.5%
Trailing year
Short interest
3.8%
Latest settlement · 3.7 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Guardian raised its full-year 2026 guidance, with revenue now expected at $1.43–$1.45 billion and adjusted EBITDA at $129–$131 million, after Q2 adjusted EBITDA grew 19% year-over-year to $29.7 million despite a 2% reported revenue increase pressured by IRA pricing reductions.
Bullish
- + Q2 adjusted EBITDA grew 19% year-over-year to $29.7 million with margin expanding to 8.4%
- + First-half adjusted EBITDA grew 23% year-over-year while mitigating IRA profitability impact
- + Q2 gross profit grew 18% year-over-year to $80 million with gross margin of 22.8%
Bearish
- − Second-half reported revenue expected to decline low single digits year-over-year from continued IRA pricing pressure
- − Recent acquisitions and greenfields continue to dilute consolidated adjusted EBITDA margin by approximately 60 basis points
- − Higher fuel costs continued to pressure gross profit in the quarter
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
−0%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
71%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+5%
trailing
6-month return
0%
trailing
YTD return
+36%
this year
Relative strength
−12%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $41 › 200d $37 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.83% of float · ▼ -20.2% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
190 holders — near 2-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+18%
Y/Y
Gross margin
20%
expanding
Balance sheet
$65.6M
net cash
Quant / Vol
risk profile
Volatility
41%
annualized · 1-yr
Max drawdown
−15%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Revenue
· FY 2026
Initiated
$1.43B – $1.45B
prior FY $1.45B
midpoint −0.6% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
−0%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
71%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $41 › 200d $37 — 50d above 200d
Institutional flow
Accumulating
+11% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.83% of float · ▼ -20.2% MoM · 3.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
190 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $23
Now $41 · 71%
Range high $48
vs 200-day avg +10%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRDN
this stock
Guardian Pharmacy Services, Inc.
|
$2.61B | +35.5% | +17.9% | — | 3.8% |
|
HCA
HCA Healthcare, Inc.
|
$96.64B | -8.6% | +7.1% | 15.0 | 2.9% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.92B | -11.6% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$20.91B | +28.6% | +0.9% | 10.0 | 2.5% |
|
EHC
Encompass Health Corp
|
$12.18B | +14.5% | +10.5% | 20.1 | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRDN | -5.7% | +4.9% | +0.3% | +10.0% | +35.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -5.1% | +4.8% | -11.9% | +10.5% | +23.7% |